Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's

Data from a new study show that patients who received Eli Lilly’s (LLY) Mounjaro (tirzepatide) significantly lost more weight than those who received Novo Nordisk’s (NVO) Wegovy (semaglutide). Both drugs are approved to treat obesity in adults.While the medications were shown to be effective in achieving weight loss, the findings indicate that Mounjaro may be more beneficial. After three months, patients taking the Lilly drug lost an average of 5.9% of their body weight compared with 3.6% for those on Novo’ ...